The annual incidence of prostate cancer more than doubled between 1984 and 1990, increasing from an estimated 76 000±200 000 cases respectively. Part of this increase may have been the result of increased detection. This study utilizes data from an American College of Surgeons Patient Care Evaluation (PCE) study to report on changes in the management of metastatic disease.
Introduction
The estimated number of new cases of prostate cancer has increased from 54 000 in 1974 1 to 209 900 in 1997. 2 During the same time period the number of estimated prostate cancer deaths rose from 18 000±41 800. The continuing impact of this cancer, relative to other signi®cant diseases such as breast cancer and AIDS, has been underestimated.
The American College of Surgeons (ACoS) has conducted three Patient Care Evaluation (PCE) studies of prostate cancer over the past twenty years. The results from the most recent of these studies, addressing patients diagnosed in 1984 and 1990, have previously been reported elsewhere. 3 Over the past six to seven years much attention has been directed toward the early detection of prostate cancer through the use of prostate speci®c antigen (PSA) and the treatment of localized disease by the nerve sparing radical prostatectomy. Indeed, PSA utilization has resulted in a dramatic stage migration and a sharp decrease in the proportion of patients diagnosed with Stage IV disease. Data reported to the National Cancer Data Base (NCDB) suggests the proportion of Stage IV prostate cancer cases has dropped from 20.4% in 1988 to 11.6% in 1993. 4 However, much of the morbidity and most, if not all, of the mortality occurs among patients diagnosed with late stage disease. The purpose of this report is to summarize the ®ndings of the most recent ACoS prostate cancer PCE study with respect to Stage IV disease Ð to review patterns of diagnosis, treatment, and survival outcomes for metastatic prostate cancer.
Methods

Sources of the data
The methodology of the American College of Surgeons Commission on Cancer PCE studies have been described previously, 5 speci®c methods employed for the 1984±1990 prostate cancer PCE study have also been discussed. 3 The present report provides detailed information for patients diagnosed with metastatic disease and includes patient demographics, diagnostic methods, and type of treatment for the two study years of 1984 and 1990. Recurrence and survival information are described only for patients diagnosed in 1984.
Approximately 2000 hospitals were invited to submit data on as many as 25 consecutive patients (for each study year) with newly diagnosed cancer of the prostate gland. Data were received from 730 hospitals for 14 
Data de®nitions
Carcinoma of the prostate gland includes cancers reported as ICD-O-2 disease topography code C61.9, according to the International Classi®cation of Diseases for Oncology. 8 Cases were staged employing the American Joint Commission on Cancer (AJCC) tumor (T), node (N), metastasis (M) staging system, 9 these stage groupings generally correspond to the American/Whitmore staging system. 10 The American/Whitmore staging system makes a distinction in late stage prostate cancer between lymph node involvement and metastasis con®ned to the pelvis (D1), and distal bony or organ metastasis (D2). The analysis in this review of the PCE study data is limited to AJCC Stage IV patients reported with distant metastatic disease (American/Whitmore stage D2). This involved selecting those cases which were reported with any T, any N, M1, and any G. The TNM staging de®ni-tions have not changed for distant metastatic prostate cancer in either the 4th or 5th editions of the AJCC cancer staging manual. 11, 12 Treatment modalities were categorized as follows: hormonal therapy was broken into three groups; orchiectomy alone, exogenous hormones alone, and combined. Exogenous hormone therapy included any one or a combination of estrogens, antiandrogens, progestational agents, or luteinizing hormone-releasing hormones. Combined hormone therapy was a treatment modality which included both orchiectomy and exogenous hormones.`Combined treatment' captured the use of hormone therapy in tandem with either radical prostectomy, radiation, or both. These same categories were maintained in the analysis of subsequent treatment modalities. Chemotherapy was employed infrequently and usually subsequent to or in combination with hormonal therapy.
All data were analyzed using SPSS, a standard statistical software package. 13 Because this PCE study was intended as a descriptive national survey of trends, and not a de®nitive evaluation of a priori hypotheses, there are no statistical signi®cance tests reported in this review. The Kaplan±Meier method of calculating survival rates was used in this analysis. Disease-speci®c mortality was the terminal event variable, patients who were reported as having died with carcinoma status unknown or with no evidence of carcinoma of the prostate gland were censored, considered alive, at the time of last follow-up evaluation. Time of survival was calculated from date of diagnosis to date of last patient contact. Where survival rates are reported following subsequent therapy the elapsed time between the start of subsequent treatment and the date of last contact was used. Calculated survival rates are not reported when fewer than 30 cases are available for analysis, in these situations the standard error tends to be large enough to erode interpretive value from the calculated survival rate. Upper and lower con®dence limits of plus or minus three standard errors are provided in conjunction with the calculation of survival rates as a general measure of variability.
Results
The total number of diagnosed cases reported to the ACoS prostate cancer PCE study was 14 716 for 1984 and 23 214 in 1990 ( Table 1 ). The proportion of cases diagnosed as AJCC Stage IV disease decreased from 25.3± 21.2% between 1984 and 1990 respectively. A total of 2895 cases were reported with AUA/Whitmore Stage D2 disease in 1984, almost a ®fth of all reported cases, and just over three quarters of the advanced stage cases. In 1990 3446 D2 cases were reported, though these cases represented a smaller proportion of all reported cases.
The average age of patients diagnosed with metastatic prostate cancer increased only slightly between 1984 and 1990, 73.3 and 74.3 y old respectively. In 1984 64.9% of patients were 70 y of age or older, compared with 69.9% in 1990.
Diagnostic methods and tests
The two principle modes by which metastatic prostate cancer was initially diagnosed, rectal examination and/or bone scan, did not change from 1984 to 1990 (Table 2) . However, the frequency with which transurethral resection of the prostate (TURP) or needle biopsy were utilized declined between the two study years. The use of TURP fell 6.5% between 1984 and 1990 while needle biopsies fell 8.3%. A similar decrease was noted in the use of perineal biopsy. In contrast, transrectal biopsies and transrectal ultrasonographically guided biopsies (TRUS) were utilized with increased frequency. This is particularly noticeable with TRUS where only 1% of reported patients in 1984 were diagnosed by TRUS. This proportion increased to over 12% by 1990.
The frequency with which tests were utilized to con®rm metastatic disease after initial diagnosis changed between 1984 and 1990, while the proportion of abnormal readings remained virtually unchanged (Table 3) . Bone scan remained the most frequently used diagnostic test, and while chest roentgenogram remained the second most utilized test, its use decreased slightly over the two study years. The use of prostate speci®c antigen (PSA) increased dramatically, from 6.3% in 1984 to 74.8% in 1990. Computed tomography (CT) and magnetic resonance imaging (MRI) were used more often while prostatic acid phosphatase, bone roentgenogram, intravenous pyelogram, and liver scans all saw decreased use.
Treatment
Hormone therapy was the most frequently utilized form of initial treatment of advanced prostate cancer, 63.7% in 1984 and 66.1% in 1990 (Table 4) . Radiation in combination with hormone therapy was the second most frequently utilized form of initial therapy, 15% in 1984 and 13.1% in 1990. Among the 1843 patients who received hormone therapy in 1984, 50% received orchiectomy, 35.2% were administered exogenous hormones, and 14.9% received a combination of both. In 1990 the proportion of men treated with hormone therapy who received orchiectomy increased to 61.7%, and those who were treated with exogenous hormones decreased to 22.5%, while 15.8% received some combination of hormone therapy. This shift away from the use of exogenous hormones also occurred among patients treated with a combination of radiation therapy and hormones. Exogenous hormones were given to 58.4% of the men who received radiation and hormone therapy in 1984, this proportion fell to 33.6% in 1990. Curative types of therapy such as radical prostatectomy and radiation therapy were employed infrequently for patients with metastatic disease. Among patients diagnosed with metastatic disease initial treatment regimes appear to have been dependent on a number of factors. The overall increase between 1985 and 1990 in the age of patients diagnosed with metastatic prostate cancer is re¯ected in the age distribution of patients receiving different types of initial treatment (Table 5 ). In 1984, the proportions of men who were 70 y of age or older who received an orchiectomy alone, exogenous hormones alone, or a combination of hormone treatments were 66.7%, 68.7% and 63.4% respectively. By 1990 the proportion of patients 70 y and older who were initially treated hormonally with only orchiectomy increased to 73.7%, while the proportion of similarly aged men treated with exogenous hormones alone dropped to 64.8%. The proportion of 70 y and older patients treated with a combination of hormone therapies changed very little between the two study years, it fell slightly to 62.4% in 1990. Changes in the age distribution among men treated by other modalities and those who received no cancer-directed treatment were also noted. In 1984 56.4% of men receiving some other treatment modality were 70 y of age or older, by 1990 this proportion increased to 63.1%. Similarly, in 1984 69.9% of patients receiving no cancer-directed treatment were 70 y of age and older, while by 1990 this proportion had increased to 79.3%.
Disease progression was reported in 90.1% of all patients diagnosed in 1984, on average 40.4% underwent some form of subsequent treatment (Table 5) . Of those patients ®rst diagnosed in 1984 who received a second course of therapy over a third were treated by radiation alone and slightly less than a quarter with hormone therapy. Over 99% of those patients subsequently treated with radiation received external beam therapy, which was largely directed toward distant metastatic sites. For those treated hormonally, over half were given exogenous hormones alone, while a third received an orchiectomy. Disease progression and subsequent treatment information is not reported for cases diagnosed in 1990 due to insuf®cient time between date of diagnosis and data of diagnosis and date of data submission to the ACoS, which resulted in incomplete availability of information.
Survival
Disease speci®c survival rates for patient age and type of initial therapy are shown in Table 6 . These ®gures indicate men 80 y of age or older had poorer ®ve-year survival experience than did patients under 80 y, 14.7% and 26.6%, on average, respectively. Although there were some reported differences in treatment category, interpretation is dif®cult in this non-randomized cohort. Similar survival rates were reported for the two primary treatment groups including orchiectomy alone (56.7% after two years and 22.5% at ®ve years) and exogenous hormones (57% after two years and 24.6% at ®ve years). Somewhat lower survival was reported for the treatment group which included patients receiving a combination of hormone therapies (50.9% after two years and 19.4% at ®ve years). Somewhat better survival (60% after two years and 32.7% at ®ve years) was reported for patients receiving radiation therapy alone. Patterns of care for metastatic prostate cancer P Guinan et al
In most cases, the calculated two-year survival rates reveal patterns similar to the ®ve-year rates with respect to treatment. While there appears to be little difference after ®ve years between orchiectomy alone, exogenous hormone therapy alone, radiation therapy combined with some sort of hormone therapy, and no cancer-directed treatment there does appear to be short-term bene®t to either orchiectomy (56.7%) or exogenous hormone therapy alone (57%) over combined hormones (50.9%), radiation plus hormonal therapy (50.8%), or no cancer-directed treatment (50.3%).
Survival rates following a second course of therapy are also shown in Table 6 . These results are reported only for those treatment combinations which had at least 30 reported cases. Patients receiving exogenous hormones followed by orchiectomy had a superior two-year survival rate (36.4%) than did patients who had an orchiectomy followed by exogenous hormone therapy (17.8%).
Discussion
The decrease in metastatic carcinoma of the prostate gland diagnoses from 19.7±14.8% of reported cases between 1984 and 1990 reverses the slight increase from 21.5% in 1974 14 to 22.6% in 1978 5 which was noted in earlier American College of Surgeons PCE studies. This decrease has been attributed, in part, to patterns of earlier diagnosis and treatment driven by the use of the PSA test. 15 The decrease in patients diagnosed under the age of 70 y, from 35.1% in 1984 to 30.1% in 1990, can probably be attributed to the increased use of the PSA test in that more younger patients would be diagnosed with lower stage disease.
Perhaps the single most important observation noted in the results of this PCE is the dramatic increase in the utilization of the PSA test, only 6.3% of reported advanced Stage IV cases received this test in 1984 whereas 74.8% were reported as having the PSA test performed in 1990. While the use of most diagnostic tests remained relatively unchanged there was an increase noted in the use of CT scans of the prostate, and a decrease in IVPs. An increase in the use of TRUS diagnoses was associated with a corresponding decrease in the utilization of both the TURP and perineal biopsy diagnoses. Screening programs utilizing PSA and TRUS have replaced the traditional digital rectal examination and subsequent perineal and TRUS biopsies. 16 Trends in the treatment of metastatic prostate cancer are somewhat more dif®cult to interpret because of the acknowledged therapeutic value of hormone therapy and the practice of combining forms of hormonal therapy (orchiectomy and exogenous hormonal agents) as well as palliative surgery (TURP) and radiotherapy (for example to metastatic bone sites). Approximately 86% of patients in both 1984 and 1990 were treated with hormone therapy (with or without radiotherapy). There was a decrease in exogenous hormone therapy from 22.3± 14.9% between the two study periods accompanied by an increase in orchiectomies from 31.8±40.7%. There was also a slight increase (13.6±14.2%) in patients being observed and receiving no cancer directed therapy. These changes re¯ect a period when the adverse cardiovascular effects of estrogens were in¯uencing therapeutic decisions. 17 Overall, the disease-speci®c survival rate was 54.8% after two years and 23.7% after ®ve years for patients diagnosed with metastatic prostate cancer. Men less than 60 y of age had superior survival outcomes when compared to men over 80 y of age. Underlying this difference may be a selection bias, younger men were probably treated more aggressively. Patients treated with hormone therapy alone, whether by orchiectomy or exogenous hormones, had better survival rates than patients treated with a combination of treatment modalities or those received no cancer directed therapy. Again, a bias may exist in that patients with heavier tumor burdens were probably treated with a combination of therapy options and did not fare as well as patients treated hormonally. While androgen deprivation is initially effective in 60± 80% of prostate cancer patients with AJCC Stage IV disease, most of these patients will progress, usually within 18±24 months. 18 Disease progression was reported in 90.1% of patients diagnosed in 1984, and less than half (40.4%) of these patients received some form of subsequent treatment (Table 4) . This is probably because it was assumed that once one form of androgen suppressive therapy failed, other types of hormonal therapy would not be bene®cial. 19 Patients treated with orchiectomy as secondary therapy following exogenous hormones had two and ®ve-year disease speci®c survival rates of 36.4 and 9.1%, respectively. Patients treated initially with exogenous hormones followed by orchiectomy had two and ®ve-year survival rates of 17.8% and 7.1%, respectively. Although the number of patients entered into the survival analysis was small (under 50 y) and the survival rates did not differ signi®cantly (con®dence interval of AE three standard errors around the calculated survival rate, P`0.01), the ®gures suggest there may be some survival advantage at two years to a secondary orchiectomy in patients with progressive disease.
Conclusion
Overall, there has been a decrease in the percent of prostate cancer patients diagnosed with metastatic disease. The PSA test and TRUS biopsy had become the principle methods of diagnosis. Hormone therapy has remained the treatment of choice, with orchiectomy being the principle form of hormone management. Orchiectomy appears to be an effective form of secondary hormone therapy.
